Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4554MR)

This product GTTS-WQ4554MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4554MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10785MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ15883MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ31MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ14344MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ13603MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ5332MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ3334MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ10097MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW